Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s RAINIER dose optimization trial evaluating mipletamig in ...

SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ...

Upfront hematopoietic stem cell transplantation (HSCT) is more cost-effective than delayed HSCT for patients with intermediate-risk acute myeloid leukemia in remission, with higher incremental net ...

90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...

The MarketWatch News Department was not involved in the creation of this content. No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently ...

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...